JOURNAL OF THE CZECH PHARMACEUTICAL SOCIETY AND THE SLOVAK PHARMACEUTICAL SOCIETY

Čes. slov. farm. 2012, 61(1):4-10

Intended pharmacotherapeutical approaches of Alzheimer's disease therapy

Jan Korábečný1,2, Eva Hrubá3, Ondřej Soukup2, Filip Zemek2, Kamil Musílek4, Eugenie Nepovímová1, Katarína Špilovská2, Veronika Opletalová1, Kamil Kuča5,*
1 Univerzita Karlova v Praze, Farmaceutická fakulta v Hradci Králové, Katedra farmaceutické chemie a kontroly léčiv
2 Univerzita obrany, Fakulta vojenského zdravotnictví, Katedra toxikologie, Hradec Králové
3 Univerzita Karlova v Praze, Farmaceutická fakulta v Hradci Králové, katedra farmakologie a toxikologie
4 Univerzita Hradec Králové, Přírodovědecká fakulta, Katedra chemie
5 Univerzita obrany, Fakulta vojenského zdravotnictví, Centrum pokročilých studií a Fakultní nemocnice Hradec Králové

Alzheimer's disease is a progressive neurodegenerative disorder mainly manifested by memory loss, personality changes, and cognitive dysfunction. Despite the fact that tireless research is being conducted, up-to-date pharmacotherapy of AD is presented only by two groups diverging in the mechanism of action. The larger one uses acetylcholinesterase inhibitors, and the second group is represented by the N-methyl-D-aspartate antagonist memantine. Even though the etiology of Alzheimer's disease is unknown, several different therapeutic approaches are being investigated. The aim of this paper is to provide an overview of the present state of intended therapeutics for AD, describing their mechanism of action if known, displaying chemical structures, and the state of clinical trials if any.

Keywords: Alzheimer's disease; acetylcholinesterase; therapeutic approaches; beta amyloid; tau protein

Received: October 13, 2011; Accepted: December 15, 2011; Published: January 1, 2012  Show citation

ACS AIP APA ASA Harvard Chicago Chicago Notes IEEE ISO690 MLA NLM Turabian Vancouver
Korábečný J, Hrubá E, Soukup O, Zemek F, Musílek K, Nepovímová E, et al.. Intended pharmacotherapeutical approaches of Alzheimer's disease therapy. Čes. slov. farm. 2012;61(1-2):4-10.
Share...
Download citation
  • BibTeX (.bib)
  • Bookends (.ris)
  • EasyBib (.ris)
  • EndNote (.enw)
  • EndNote 8 (.xml)
  • ISI WoS (.isi)
  • Medlars (.medlars)
  • Mendeley (.ris)
  • MODS (.xml)
  • Papers (.ris)
  • RefWorks (.txt)
  • RefManager (.ris)
  • RIS (.ris)
  • MS Word (.xml)
  • Zotero (.ris)
    • Open full article

    References

    1. Alzheimer's Association. 2011 Alzheimer's disease facts and figures. Alzheimers Dement 2011; 7, 208-244. Go to original source... Go to PubMed...
    2. Herrup K. Re imaginizing Alzheimer' disease - an age-based hypothesis. J Neurosci 2010; 30, 16755-16762 Go to original source... Go to PubMed...
    3. Drtinova L., Pohanka M. Alzheimerova demence: aspekty současné farmakologické léčby. Čes slov Farm 2011; 60, 219-228.
    4. Craig D., Mirakhur A., Hart D. J., McIlroy S. P., Passmore A. P. A cross-sectional study of neuropsychiatric symptoms in 435 patients with Alzheimer's disease. Am J Geriat Psychiat 2005; 13, 460-468. Go to original source...
    5. Ballard C., Gauthier S., Corbett A., Brayne C., Aarsland D., Jones E. Alzheimer's disease. Lancet 2011; 377, 1019-1031. Go to original source... Go to PubMed...
    6. Brodaty H., Breteler M. M., Dekosky S. T., Dorenlot P., Fratiglioni L., Hock C., Kenigsberg P. A., Scheltens P., De Strooper B. The world of dementia beyond 2020. J Am Geriatr Soc 2011; 59, 923-927.
    7. Souder E., Beck C. Overview of Alzheimer's disease. Nurs Clin N Am 2004; 39, 545-559. Go to original source... Go to PubMed...
    8. Kim K. Y., Wood B. E., Wilson M. I. Risk factors for Alzheimer's disease: An overview for clinical practitioners. Consult Pharm 2005; 20, 224-230. Go to original source... Go to PubMed...
    9. Bateman R. J., Aisen P. S., De Strooper B., Fox N. C., Lemere C. A., Ringman J. M., Salloway S., Sperling R. A., Windisch M., Xiong C. Autosomal-dominant Alzheimer's disease: a review and proposal for the prevention of Alzheimer's disease. Alzheimers Res Ther 2011; 3, 1-13. Go to original source... Go to PubMed...
    10. Giacobini E. Do cholinesterase inhibitors have disease-modifying effects in Alzheimer's disease? CNS Drugs 2001; 15, 85-91. Go to original source... Go to PubMed...
    11. Giacobini E., Mori F., Lai C. C. The effect of cholinesterase inhibitors on the secretion of APPS from rat brain cortex. Ann NY Acad Sci. 1996; 777, 393-398. Go to original source... Go to PubMed...
    12. Knapp M. J., Knopman D. S., Solomon P. R., Pendlebury W. W., Davis C. S., Gracon S. I. A 30-week randomized controlled trial of high-dose tacrine in patients with Alzheimer's disease. JAMA 1994; 271, 985-991. Go to original source...
    13. Dejmek L. 7-Meota. Drug Future 1990; 15, 126-129. Go to original source...
    14. Korabecny J., Musilek K., Holas O., Binder J., Zemek F., Marek J., Pohanka M., Opletalova V., Dohnal V., Kuca K. Synthesis and in vitro evaluation of N-alkyl-7-methoxytacrine hydrochlorides as potential cholinestrase inhibitors in Alzhemeir disease. Bioorg Med Chem Lett 2010; 20, 6093-6095. Go to original source... Go to PubMed...
    15. Korabecny J., Holas O., Musilek K., Pohanka M., Opletalova V., Dohnal V., Kuca K. Synthesis and in vitro evaluation of new tacrine derivatives-bis-alkylene linked 7-MEOTA. Lett Org Chem 2010; 7, 327-331. Go to original source...
    16. Korabecny J., Musilek K., Holas O., Nepovimova E., Jun D., Zemek F., Opletalova V., Patocka J., Dohnal V., Nachon F., Hroudova J., Fisar Z., Kuca K. Synthesis and in vitro evaluation of N-(bromobut-3-en-2-yl)-7-methoxy-1,2,3,4-tetrahydroacridin-9-amine as a cholinesterase inhibitor with regard to Alzheimer's disease treatment. Molecules 2010; 15, 8804-8812. Go to original source... Go to PubMed...
    17. Korabecny J., Musilek K., Zemek F., Horova A., Holas O., Nepovimova E., Opletalova V., Hroudova J., Fisar Z., Jung Y.-S., Kuca K. Synthesis and in vitro evaluation of 7-methoxy-N-(pent-4-enyl)-1,2,3,4-tetrahydroacridin-9-amine - new tacrine derivative with cholinergic properties. Bioorg Med Chem Lett 2011; 21, 6563-6556. Go to original source... Go to PubMed...
    18. Fang L, Appenroth D., Decker M., Kiehntopf M., Lupp A., Peng S., Fleck C., Zhang Y., Lehman J. NO-donating tacrine hybrid compounds improve scopolamine-induced cognition impairment and show less hepatotoxicity. J Med Chem 2008; 51, 7666-7669. Go to original source... Go to PubMed...
    19. Trinh, N. H., Hoblyn, J., Mohanty, S., Yaffe, K. Efficacy of cholinesterases inhibitors in the treatment of neuropsychiatric symptoms and functional impairment in Alzheimer disease: a meta-analysis. JAMA 2003; 289, 210-216. Go to original source... Go to PubMed...
    20. Kamal, M. A., Klein, P., Yu, Q. S., Tweedie, D., Li, Y., Holloway, H. W., Tweedie, D., Greig, N. H. Kinetics of human serum butyrylcholinesterase and its inhibition by a novel experimental Alzheimer therapeutic, bisnorcymserine. J Alzheimers Dis 2006; 10, 43-51. Go to original source... Go to PubMed...
    21. Li F., Tsien J. Z. Memory and the NMDA receptors. New Engl J Med 2009; 361, 302-303. Go to original source... Go to PubMed...
    22. Harkany T., Abraham I., Timmerman W., Laskay G., Toth B., Safari M., Konya C., Sebens J. B., Korf J., Nyakas C., Zarandi M., Soos K., Penke B., Luiten P. G. Beta-amyloid neurotoxicity is mediated by a glutamate-triggered excitotoxic cascade in rat nucleus basalis. Eur J Neurosci 2000; 12, 2735-2745. Go to original source... Go to PubMed...
    23. Amadoro G., Ciotti M. T., Costanzi M., Cestari V., Calissano P., Canu N. NMDA receptor mediates tau-induced neurotoxicity by calpain and ERK/MAPK activation. P Natl Acad Sci USA 2006; 103, 2892-2897. Go to original source... Go to PubMed...
    24. Sonkusare S. K., Kaul C. L., Ramarao P. Dementia of Alzheimer's disease and other neurodegenerative disorders-memantine, a new hope. Pharmacol Res 2005; 51, 1-17. Go to original source... Go to PubMed...
    25. Tariot P. N., Farlow M. R., Grossberg G. T., Graham S. M., McDonald S., Gergel I. Memantine treatment in patients with moderate to severe Alzheimer disease already receiving donepezil: a randomized controlled trial. JAMA 2004; 291, 317-324. Go to original source... Go to PubMed...
    26. Wenk G. L., Baker L. M., Stoehr J. D., Hauss-Wegrzyniak B., Danysz W. Neuroprotection by novel antagonists at the NMDA receptor channel and glycineB sites. Eur J Pharmacol. 1998; 347, 183-187. Go to original source... Go to PubMed...
    27. Schenk D., Barbour R., Dunn W., Gordon G., Grajeda H., Guido T., Hu K., Huang J., Johnson-Wood K., Khan K., Kholodenko D., Lee M., Liao Z., Lieberburg I., Motter R., Mutter L., Soriano F., Shopp G., Vasquez N., Vandevert C., Walker S., Wogulis M., Yednock T., Games D., Seubert P. Immunization with amyloid-beta attenuates Alzheimer-disease-like pathology in the PDAPP mouse. Nature 1999; 400, 173-177. Go to original source... Go to PubMed...
    28. Lavie V., Becker M., Cohen-Kupiec R., Yacoby I., Koppel R., Wedenig M., Hutter-Paier B., Solomon B. EFRH-phage immunization of Alzheimer's disease animal model improves behavioral performance in Morris water maze trials. J Mol Neurosci 2004; 24, 105-113. Go to original source... Go to PubMed...
    29. Orgogozo J. M., Gilman S., Dartigues J. F., Laurent B., Puel M., Kirby L. C., Jouanny P., Dubois B., Eisner L., Flitman S., Michel B. F., Boada M., Frank A., Hock C. Subacute meningoencephalitis in a subset of patients with AD after A beta 42 immunization. Neurology 2003; 61, 46-54. Go to original source... Go to PubMed...
    30. Hock C., Konietzko U., Streffer J. R., Tracy J., Signorell A., Müller-Tillmanns B., Lemke U., Henke K., Moritz E., Garcia E., Wollmer M. A., Umbricht D., de Quervain D. J., Hofmann M., Maddalena A., Papassotiropoulos A., Nitsch R. M. Antibodies against beta-amyloid slow cognitive decline in Alzheimer's disease. Neuron 2003; 38, 547-554. Go to original source... Go to PubMed...
    31. Fox N. C., Black R. S., Gilman S., Rossor M. N., Griffith S. G., Jenkins L., Koller M. Effects of A beta immunization (AN1792) on MRI measures of cerebral volume in Alzheimer disease. Neurology 2005; 64, 1563-1572. Go to original source... Go to PubMed...
    32. Dodel R. C., Du Y., Depboylu C., Hampel H., Frölich L., Haag A., Hemmeter U., Paulsen S., Teipel S. J., Brettschneider S., Spottke A., Nölker C., Möller H. J., Wei X., Farlow M., Sommer N., Oertel W. H. Intravenous immunoglobulins containing antibodies against beta-amyloid for the treatment of Alzheimer's disease. J Neurol Neurosur Ps 2004; 75, 1472-1474. Go to original source... Go to PubMed...
    33. Asai M., Hattori C., Iwata N., Saido T. C., Sasagawa N., Szabó B., Hashimoto Y., Maruyama K., Tanuma S., Kiso Y., Ishiura S. The novel beta-secretase inhibitor KMI-429 reduces amyloid beta peptide production in amyloid precursor protein transgenic and wild-type mice. J Neurochem 2006; 96, 533-540. Go to original source... Go to PubMed...
    34. Wong P. BACE. Alzheimers Dement 2005; 1, S3. Go to original source...
    35. Citron M. Beta-secretase inhibition for the treatment of Alzheimer's disease-promise and challenge. Trends Pharmacol Sci 2004; 25, 92-97. Go to original source... Go to PubMed...
    36. Mancini F., de Simone A., Andrisano V. Beta-secretase as a target for Alzheimer's disease drug discovery: an overview of in vitro methods for characterization of inhibitors. Anal Bioanal Chem 2011; 400, 1979-1996. Go to original source... Go to PubMed...
    37. Lanz T. A., Himes C. S., Pallante G., Adams L., Yamazaki S., Amore B., Merchant K. M. The gamma-secretase inhibitor N-[N-(3,5-difluorophenacetyl)-L-alanyl]-S-phenylglycine t-butyl ester reduces A beta levels in vivo in plazma and cerebrospinal fluid in young (plaque-free) and aged (plaque-bearing) Tg2576 mice. J Pharmacol Exp Ther 2003; 305, 864-871. Go to original source... Go to PubMed...
    38. El Mouedden M., Vandermeeren M., Meert T., Mercken M. Reduction of A beta levels in the Sprague Dawley rat after oral administrativ of the functional gamma-secretase inhibitor, DAPT: a novel non-transgenic model for A beta production inhibitors. Curr Pharm Design 2006; 12, 671-676. Go to original source... Go to PubMed...
    39. May P. C., Yang Z., Li W., Hyslop P. A., Siemers E., Boggs L. N. Multi-compartmental pharmacodynamic assessment of the functional gamma-secretase inhibitor LY450139 dihydrate in PDAPP transgenic mice and non-transgenic mice. Neurobiol Aging 2004; 25, S65. Go to original source...
    40. Barten D. M., Guss V. L., Cosa J. A., Loo A., Hansel S. B., Zheng M., Munoz B., Srinivasan K., Wang B., Robertson B. J., Polson C. T., Wang J., Roberts S. B., Hendrick J. P., Anderson J. J., Loy J. K., Denton R., Verdoorn T. A., Smith D. W., Felsenstein K. M. Dynamics of {beta}-amyloid reductions in brain, cerebrospinal fluid, and plasma of {beta}-amyloid precursor protein transgenic mice treated with a {gamma}-secretase inhibitor. J Pharmacol Exp Ther 2005; 312, 635-643. Go to original source... Go to PubMed...
    41. Imbimbo B. P. Alzheimer's disease: gamma secretase inhibitors. Drug Discov Today: Therapeutic Strategies 2008; 5, 169-175. Go to original source...
    42. Weggen S., Eriksen J. L., Sagi S. A., Pietrzik C. U., Golde T. E., Koo E. H. A beta 42-lowering nonsteroidal anti-inflammatory drugs preserve intramembrane cleavage of the amyloid precursor protein (APP) and ErbB-4 receptor and signaling through the APP intracellular domain. J Biol Chem 2003; 278, 30748-30754. Go to original source... Go to PubMed...
    43. Becker R. E., Greig N. H. Why so few drugs for Alzheimer's disease? Are methods failing drugs? Curr Alzheimer Res 2010; 7, 642-651. Go to original source... Go to PubMed...
    44. Mintzer J. E., Wilcock G. K., Black S. E., Zavitz K. H., Hendrix S. B. MPC-7869, a selective Abeta42-lowering agent, delays time to clinically significant psychiatric adverse events in Alzheimer's disease: analysis from a 12-month phase 2 trial. Presented as a poster exhibit at the 10th International Conference on Alzheimer's Disease and Related Disorders; 2006 Jul 15-20; Madrid, Spain. Go to original source...
    45. Aisen P. S., Gauthier S., Vellas B., Briand R., Saumier D., Laurin J., Garceau D. Alzhemed: A potential treatment for Alzheimer's disease. Curr Alzheimer Res 2007; 4, 473-478. Go to original source... Go to PubMed...
    46. Bilikiewicz A., Gaus W. Colostrinin (a naturally occurring, proline-rich, polypeptide mixture) in the treatment of Alzheimer's disease. J Alzheimer Dis 2004; 6, 17-26. Go to original source... Go to PubMed...
    47. Leszek J., Inglot A. D., Janusz M., Byczkiewicz F., Kiejna A., Georgiades J., Lisowski J. Colostrinin proline-rich polypeptide complex from ovine colostrum-a long-term study of its efficacy in Alzheimer's disease. Med Sci Monitor 2002; 8, PI93-PI96.
    48. Townsend M., Cleary J. P., Mehta T., Hofmeister J., Lesne S., O'Hare E., Walsh D. M., Selkoe D. J. Orally available compound prevents deficits in memory caused by the Alzheimer amyloid-beta oligomers. Ann Neurol 2006; 60, 668-676. Go to original source... Go to PubMed...
    49. Fassbender K., Simons M., Bergmann C., Stroick M., Lutjohann D., Keller P., Runz H., Kuhl S., Bertsch T., von Bergmann K., Hennerici M., Beyreuther K., Hartmann T. Simvastatin strongly reduces levels of Alzheimer's disease beta-amyloid peptides A beta 42 and A beta 40 in vitro and in vivo. P Natl Acad Sci USA 2001; 98, 5856-5861. Go to original source... Go to PubMed...
    50. Wolozin B., Kellman W., Ruosseau P., Celesia G. G., Siegel G. Decreased prevalence of Alzheimer disease associated with 3-hydroxy-3-methylglutaryl coenzyme A reductase inhibitors. Arch Neurol 2000; 57, 1439-1443. Go to original source... Go to PubMed...
    51. Li G., Higdon R., Kukull W. A., Peskind E., Moore K. V., Tsuang D., van Belle G., McCormick W., Bowen J. D., Teri L., Schellenberg G. D., Larson E. B. Statin therapy and risk of dementia in the elderly: a community-based prospective cohort study. Neurology 2004; 63, 1624-1628. Go to original source... Go to PubMed...
    52. Jick H., Zornberg G. L., Jick S. S., Seshadri S., Drachman D. A. Statins and the risk of dementia. Lancet 2000; 356, 1627-1631. Go to original source... Go to PubMed...
    53. Rockwood K., Kirkland S., Hogan D. B., MacKnight C., Merry H., Verreault R., Wolfson C., McDowell I. Use of lipid-lowering agents, indication bias, and the risk of dementia in community-dwelling elderly people. Arch Neurol 2002; 59, 223-227. Go to original source... Go to PubMed...
    54. McGuiness B., O'Hare J., Craig D., Bullock R., Malouf R., Passmore P. Statins for the treatment of dementia (Review). Cochrane Database Syst Rev 2010; 4. Go to original source... Go to PubMed...
    55. Yaffe K., Barrett-Connor E., Lin F., Grady D. Serum lipoprotein levels, statin use, and cognitive function in older women. Arch Neurol 2002; 59, 378-384. Go to original source... Go to PubMed...
    56. Rea T. D., Breitner J. C., Psaty B. M., Fitzpatrick A. L., Lopez O. L., Newman A. B., Hazzard W. R., Zandi P. P., Burke G. L., Lyketsos C. G., Bernick C., Kuller L. H. Statin use and the risk of incident dementia: the cardiovascular health study. Arch Neurol 2005; 62, 1047-1051. Go to original source... Go to PubMed...
    57. Shepherd J., Blauw G. J., Murphy M. B., Bollen E. L., Buckley B. M., Cobbe S. M., Ford I., Gaw A., Hyland M., Jukema J. W., Kamper A. M., Macfarlane P. W., Meinders A. E., Norrie J., Packard C. J., Perry I. J., Stott D. J., Sweeney B. J., Twomey C., Westendorp R. G.; PROSPER study group. PROspective Study of Pravastatin in the Elderly at Risk. Pravastatin in elderly individuals at risk of vascular disease (PROSPER): a randomised controlled trial. Lancet 2002; 360, 1623-1630. Go to original source... Go to PubMed...
    58. Zandi P. P., Sparks D. L., Khachaturian A. S., Tschanz J., Norton M., Steinberg M., Welsh-Bohmer K. A., Breitner J. C.; Cache County Study investigators. Do statins reduce risk of incident dementia and Alzheimer disease? The Cache County Study. Arch Gen Psychiatry 2005; 62, 217-224. Go to original source... Go to PubMed...
    59. Wang Q., Yan J., Chen X., Li J., Yang Y., Weng J., Deng C., Yenari M. A. Statins: multiple neuroprotective mechanisms in neurodegenerative diseases. Exp Neurol 2011; 230, 27-34. Go to original source... Go to PubMed...
    60. Craft S. Insulin resistance syndrome and Alzheimer's disease: age- and obesity-related effects on memory, amyloid, and inflammation. Neurobiol Aging 2005; 26, S65-S69. Go to original source... Go to PubMed...
    61. Pedersen W. A., McMillan P. J., Kulstad J. J., Leverenz J. B., Craft S., Haynatzki G. R. Rosiglitazone attenuates learning and memory deficits in Tg2576 Alzheimer mice. Exp Neurol 2006; 199, 265-273. Go to original source... Go to PubMed...
    62. Watson G. S., Cholerton B. A., Reger M. A., Baker L. D., Plymate S. R., Asthana S., Fishel M. A., Kulstad J. J., Green P. S., Cook D. G., Kahn S. E., Keeling M. L., Craft S. Preserved cognition in patients with early Alzheimer disease and amnestic mild cognitive impairment during treatment with rosiglitazone: a preliminary study. Am J Geriat Psychiat 2005; 13, 950-958. Go to original source...
    63. Geldmacher D. S., Frolich L., Doody R. S., Erkinjuntti T., Vellas B., Jones R. W., Banerjee S., Lin P., Sano M. Realistic expectations for treatment success in Alzheimer's disease. J Nutr Health Aging 2006; 10, 417-429.
    64. Craft S. Insulin resistance syndrome and Alzheimer disease: pathophysiologic mechanisms and therapeutic implications. Alz Dis Assoc Dis 2006; 20, 298-301. Go to original source... Go to PubMed...
    65. Gupta A., Bisht B., Dey C. S. Peripheral insulin-sensitizer drug metformin ameliorates neuronal insulin resistance and Alzheimer's-like changes. Neuropharmacology 2011; 60, 910-920. Go to original source... Go to PubMed...
    66. Cuajungco M. P., Frederickson C. J., Bush A. I. Amyloid-beta metal interaction and metal chelation. Sub-Cell Biochem 2005; 38, 235-254. Go to original source... Go to PubMed...
    67. Cherny R. A., Atwood C. S., Xilinas M. E., Gray D. N., Jones W. D., McLean C. A., Barnham K. J., Volitakis I., Fraser F. W., Kim Y., Huang X., Goldstein L. E., Moir R. D., Lim J. T., Beyreuther K., Zheng H., Tanzi R. E., Masters C. L., Bush A. I. Treatment with a copper-zinc chelator markedly and rapidly inhibits beta-amyloid accumulation in Alzheimer's disease transgenic mice. Neuron 2001; 30, 665-676. Go to original source... Go to PubMed...
    68. Ritchie C. W., Bush A. I., Mackinnon A., Macfarlane S., Mastwyk M., MacGregor L., Kiers L., Cherny R., Li Q. X., Tammer A., Carrington D., Mavros C., Volitakis I., Xilinas M., Ames D., Davis S., Beyreuther K., Tanzi R. E., Masters C. L. Metal-protein attenuation with iodochlorhydroxyquin (clioquinol) targeting Abeta amyloid deposition and toxicity in Alzheimer disease: a pilot phase 2 clinical trial. Arch Neurol 2003; 60, 1685-1691. Go to original source... Go to PubMed...
    69. Dedeoglu A., Cormier K., Payton S., Tseitlin K. A., Kremsky J. N., Lai L., Li X., Moir R. D., Tanzi R. E., Bush A. I., Kowall N. W., Rogers J. T., Huang X. Preliminary studies of a novel bifunctional metal chelator targeting Alzheimer's amyloidogenesis. Exp Gerontol 2004; 39, 1641-1649. Go to original source... Go to PubMed...
    70. Lee J. Y., Friedman J. E., Angel I., Kozak A., Koh J. Y. The lipophilic metal chelator DP-109 reduces amyloid pathology in brains of human beta-amyloid precursor protein transgenic mice. Neurobiol Aging 2004; 25, 1315-1321. Go to original source... Go to PubMed...
    71. Reznichenko L., Amit T., Zheng H., Avramovich-Tirosh Y., Youdim M. B., Weinreb O., Mandel, S. Reduction of iron-regulated amyloid precursor protein and beta-amyloid peptide by (-)-epigallocatechin-3-gallate in cell cultures: implications for iron chelation in Alzheimer's disease. J Neurochem 2006; 97, 527-536. Go to original source... Go to PubMed...
    72. Fisher A., Pittel Z., Haring R., Bar-Ner N., Kliger-Spatz M., Natan N., Egozi I., Sonego H., Marcovitch I., Brandeis R. M1 muscarinic agonists can modulate some of the hallmarks in Alzheimer's disease: implications in future therapy. J Mol Neurosci 2003; 20, 349-356. Go to original source... Go to PubMed...
    73. Fisher A., Brandeis R., Bar-Ner R. H., Kliger-Spatz M., Natan N., Sonego H., Marcovitch I., Pittel Z. AF150(S) and AF267B: M1 muscarinic agonists as innovative therapies for Alzheimer's disease. J Mol Neurosci 2002; 19, 145-153. Go to original source... Go to PubMed...
    74. Caccamo A., Fisher A., Laferla F. M. M1 Agonists as a potential disease-modifying therapy for Alzheimer's disease. Curr Alzheimer Res 2009; 6, 112-117. Go to original source... Go to PubMed...
    75. Caccamo A., Oddo S., Billings L. M., Green K. N., Martinez-Coria H., Fisher A., LaFerla F. M. M1 receptors play a central role in modulating AD-like pathology in transgenic mice. Neuron 2006; 49, 671-682. Go to original source... Go to PubMed...
    76. Hock C., Maddalena A., Raschig A., Müller-Spahn F., Eschweiler G., Hager K., Heuser I., Hampel H., Müller-Thomsen T., Oertel W., Wienrich M., Signorell A., Gonzalez-Agosti C., Nitsch R. M. Treatment with the selective muscarinic m1 agonist talsaclidine decreases cerebrospinal fluid levels of A beta (42) in patients with Alzheimer's disease. Amyloid 2003; 10, 1-6. Go to original source... Go to PubMed...
    77. Bodick N. C., Offen W. W., Levey A. I., Cutler N. R., Gauthier S. G., Satlin A., Shannon H. E., Tollefson G. D., Rasmussen K., Bymaster F. P., Hurley D. J., Potter W. Z., Paul S. M. Effects of xanomeline, a selective muscarinic receptor agonist, on cognitive function and behavioral symptoms in Alzheimer disease. Arch Neurol 1997; 54, 465-473. Go to original source... Go to PubMed...
    78. Fang L., Jumpertz S., Zhang Y., Appenroth D., Fleck C., Mohr K., Tränkle C., Decker M. Hybrid molecules from xanomeline and tacrine: enhanced tacrine actions on cholinesterases and muscarinic M1 receptors. J Med Chem 2010; 53, 2094-2103. Go to original source... Go to PubMed...
    79. Mulugeta E., Karlsson E., Islam A., Kalaria R., Mangat H., Winblad B., Adem A. Loss of muscarinic M4 receptors in hippocampus of Alzheimer patients. Brain Res 2003; 960, 259-262. Go to original source... Go to PubMed...
    80. Heinrich JN, Butera JA, Carrick T, Kramer A, Kowal D, Lock T, Marquis KL, Pausch MH, Popiolek M, Sun SC, Tseng E, Uveges AJ, Mayer SC. Pharmacological comparison of muscarinic ligands: historical versus more recent muscarinic M1-preferring receptor agonists. Eur J Pharmacol 2009; 605, 53-56. Go to original source... Go to PubMed...
    81. Neeper M., Schmidt A. M., Brett J., Yan S. D., Wang F., Pan Y. C., Elliston K., Stern D., Shaw A. Cloning and expression of a cell-surface receptor for advanced glycosylation end-products of proteins. J Biol Chem 1992; 267, 14998-15004. Go to original source...
    82. Mackic J. B., Stins M., McComb J. G., Calero M., Ghiso J., Kim K. S., Yan S. D., Stern D., Schmidt A. M., Frangione B., Zlokovic B. V. Human blood-brain barrier receptors for Alzheimer's amyloid-h 1-40. Asymmetrical binding, endocytosis, and transcytosis at the apical side of brain microvascular endothelial cell monolayer. J Clin Invest 1998; 102, 734-743. Go to original source... Go to PubMed...
    83. Deane R., Du Yan S., Submamaryan R. K., LaRue B., Jovanovic S., Hogg E., Welch D., Manness L., Lin C., Yu J., Zhu H., Ghiso J., Frangione B., Stern A., Schmidt A. M., Armstrong D. L., Arnold B., Liliensiek B., Nawroth P., Hofman F., Kindy M., Stern D., Zlokovic B. RAGE mediates amyloid-beta peptide transport across the blood-brain barrier and accumulation in brain. Nat Med 2003; 9, 907-913. Go to original source... Go to PubMed...
    84. Matsuoka Y., Saito M., LaFrancois J., Saito M., Gaynor K., Olm V., Wang L., Casey E., Lu Y., Shiratori C., Lemere C., Duff K. Novel therapeutic approach for the treatment of Alzheimer's disease by peripheral administration of agents with an affinity to betaamyloid. J Neurosci 2003; 23, 29-33. Go to original source... Go to PubMed...
    85. Bachmeier C., Beaulieu-Abdelahad D., Mullan M., Paris D. Selective dihydropyiridine compounds facilitate the clearance of β-amyloid across the blood-brain barrier. Eur J Pharmacol 2011; 659, 124-129. Go to original source... Go to PubMed...

    Return to the content


    Czech and Slovak Pharmacy

    Madam, Sir,
    please be aware that the website on which you intend to enter, not the general public because it contains technical information about medicines, including advertisements relating to medicinal products. This information and communication professionals are solely under §2 of the Act n.40/1995 Coll. Is active persons authorized to prescribe or supply (hereinafter expert).
    Take note that if you are not an expert, you run the risk of danger to their health or the health of other persons, if you the obtained information improperly understood or interpreted, and especially advertising which may be part of this site, or whether you used it for self-diagnosis or medical treatment, whether in relation to each other in person or in relation to others.

    I declare:

    1. that I have met the above instruction
    2. I'm an expert within the meaning of the Act n.40/1995 Coll. the regulation of advertising, as amended, and I am aware of the risks that would be a person other than the expert input to these sites exhibited

    No
    Yes

    If your statement is not true, please be aware
    that brings the risk of danger to their health or the health of others.